Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Investor Presentation (May 2024)
25 slides from Optiscan Imaging's investor presentation, May 16, 2024
Slide 1: Optiscan Webinar Investor Presentation
ASX Announcement 16 May 2024 (Melbourne, Australia) Optiscan Imaging Ltd (ASX:OIL) Optiscan Webinar Investor Presentation Optiscan Imaging Limited (ASX:OIL) (‘Optiscan’ or ‘The Company’) is pleased to release an updated investor presentation ahead of the Company’s Chief Executive Officer and Managin
Slide 2: Patent-Protected Proprietary Technology
Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen- sized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim
Slide 3: Investor Update
Optiscan Imaging Ltd (ASX:OIL) Investor Update, 16 May 2024 The new standard of care in digital pathology and precision surgery
Slide 4: Disclaimer
Disclaimer This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 16 May 2024. The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor ma
Slide 5: Presenter
Presenter Dr Camile Farah MBA, PhD, MAICD, FAIM, FLWA CEO & Managing Director, Optiscan Imaging Ltd (ASX:OIL) President & CEO, Optiscan Imaging, Inc. cfarah@optiscan.com /company/Optiscan www.optiscan.com
Slide 6: Optiscan At A Glance
Optiscan At A Glance A global medical technology company leading the transformation of digital pathology and precision surgery ASX: OIL Melbourne $ 100m Patent Proven Validated Team 2,350 m2 QMS Minnesota 1997 Headquarters Market Cap Protected Technology Products Agile Office & Plant Certification C
Slide 7: Proven + Validated Technology
Proven + Validated Technology
Slide 8: Current Clinical Applications: Large, Relevant Markets
Current Clinical Applications: Large, Relevant Markets Cancer Cases Healthcare Spend Breast o Total US addressable market in breast cancer surgery is US$2.6 bn. o Total recurrence costs for breast cancer 100 50k surgery are over US$6.4 bn. Optiscan o Potential to reduce breast lumpectomy Focus Are
Slide 9: Larger Opportunity Ahead of Us
Larger Opportunity Ahead of Us To date, Optiscan has focused on a portion of the healthcare market opportunity. The digital health space presents a sizeable and lucrative opportunity for future growth. THE OPPORTUNITY The global AI The global digital healthcare market health market is size was estim
Slide 10: Digital Product Range: Hardware + Software
Digital Product Range: Hardware + Software Clinical Product Family Vision Oral Cervical Surgical Pathology GI Vet + Developing a Full Suite of Digital Health Assets Intraoperative Telepathology & Remote AI Based Identification Biopsy Channel Compatible Integration with Robotics Image-guided Diagnost
Slide 11: Optiscan's Transformation Journey
Optiscan’s Transformation Journey Optiscan continues to evolve and build upon its strong foundation. Operational enhancements, strategic investments and product development have positioned us for the next phase of strategic growth. Phase 1: Core foundation Phase 2: Strategic transformation Phase
Slide 12: Strategic Transformation – Progress to Date
Strategic Transformation – Progress to Date Structural changes to optimise efficiencies Qualify global market opportunity Establish US operations Segment high growth sectors Operations Sales Established US sales presence across North Introduce expertise and dedicated resources in strateg
Slide 13: Bridging the Gap between Surgery and Pathology
11 Bridging the Gap between Surgery and Pathology Clinical Product Family Vision Oral Cervical Surgical Pathology GI Vet + Developing a Full Suite of Digital Health Assets Intraoperative Telepathology & Remote AI Based Identification Biopsy Channel Compatible Integration with Robotics Image-guided D
Slide 14: The Next Step in our Evolution
The Next Step in our Evolution Developing a Full Suite of Digital Health Assets Intraoperative Telepathology & Remote AI Based Identification Biopsy Channel Compatible Integration with Robotics Image-guided Diagnostics & Diagnostics Devices Systems Molecular Surgery
Slide 15: A Strategic Collaboration with Unlimited Potential
A Strategic Collaboration with Unlimited Potential o The Mayo Clinic agreement represents a significant milestone in Optiscan’s evolution. o As the largest integrated, not-for-profit medical group practice in the world, Mayo Clinic’s collaboration with Optiscan demonstrates the legitimacy and potent
Slide 16: Mayo Clinic
Mayo Clinic o Mayo Clinic is the largest integrated, not-for-profit medical group practice in the world. Recent advances include: o Mayo Clinic has a vision of transforming medicine to connect and cure as the global authority in the care of serious or complex disease. o Transplant - 1,858 solid orga
Slide 17: Robotic-Assisted Surgery
Robotic-Assisted Surgery US Forecasted 2024 Incidence of Cancers Serviced by Robotics Industry o The integration of Optiscan technology into 300,000 robotic systems will open further opportunities Cancers within the reported top 10 common cancer types by US National in the oncology market currently
Slide 18: The Gateway to Robotic-Assisted Surgery
The Gateway to Robotic-Assisted Surgery Highest Resolution, Greatest Accuracy, Growing Markets
Slide 19: Strategic Growth – Product Lifecycle
Strategic Growth – Product Lifecycle Oral IDEATION PROTOTYPING PRECLINICAL CLINICAL REGULATORY LAUNCH MONITORING Breast IDEATION PROTOTYPING PRECLINICAL CLINICAL REGULATORY LAUNCH MONITORING Pathology IDEATION PROTOTYPING PRECLINICAL CLINICAL REGULATORY LAUNCH MONITORING Telepathology IDEATION PROTO
Slide 20: Clinical + Regulatory Pathways
Clinical + Regulatory Pathways Optiscan remains agile and diligent as we adjust to changing US regulatory legislation. We remain focused on accelerating our path to achieve FDA approval. Device Device & Drug Combination Products Oral o Incorporate FDA feedback and new legislative requirements in
Slide 21: Optiscan's Growing Footprint & Sales Pipeline
Optiscan’s Growing Footprint & Sales Pipeline Rochester, United States Regional Office Clinical & Regulatory Affairs European Union Business Development Sales & Marketing Beijing, China Chicago, United States Distribution Business Development Sinsi Technologies Ltd Sales & Marketing Portland, United
Slide 22: Financial Summary
Financial Summary Financial Position Projected Revenue Cash & term deposits $12.2 m Current assets $15.3 m Million 6 Current liabilities $1.2 m Working capital $14.1 m -4 Y1 Y2 Y3 Y4 Y5 Revenue Net Profit Top Shareholders Capital Allocation 1% 1% R&D Peter Investments Production & operations Clermon
Slide 23: Continuing the Momentum
Continuing the Momentum Optiscan has pivoted from an ambiguous OEM provider to a strategically focused, diversified, and optimized business. The foundation we have laid positions us for legitimate growth and a path to become a global innovator in digital health. Our collaboration with Mayo Cli
Slide 24: Contact Us
Contact Us Shareholder & General Enquiries Media & Investor Enquiries Optiscan Imaging Ltd The Capital Network Dr Camile Farah Russell Katz T: +61 3 9538 3333 T: +61 2 8999 3699 E: ceo@optiscan.com E: russell@thecapitalnetwork.com.au Visit us at optiscan.com Connect with us on LinkedIn X or Instagra
Slide 25: Optiscan
Optiscan”